DEC 24, 2015 10:32 AM PST

Immunotherapy Better for Non-Small-Cell Lung Cancer Patients

WRITTEN BY: Kara Marker
Some tumor cells in patients with non-small-cell lung cancer (NSCLC) express programmed death ligand 1 (PD-L1) that binds to its receptor (PD-1) which is expressed by immune cells. This interaction inhibits T cells’ ability to attack cancerous cells, allowing the tumor to grow unimpeded (Oncology). In attempt to block this inhibition, scientists are developing an immunotherapy that targets PD-1 and allows T cells to properly fight off growing cancer cells.

From the University of California, Los Angeles, researchers studied a group of patients with NSCLC to see how PD-1 immunotherapy compares with traditional chemotherapy.  Out of over a thousand participants, 75 percent had at least one percent of PD-L1 expressed by their tumor cells. The study results, which were published in The Lancet, showed groups of NSCLC patients receiving the PD-1 immunotherapy both experienced significant tumor shrinkage and lived longer than the patients who received chemotherapy.

"For most patients, this now offers data showing that immunotherapy leads to superior clinical outcomes with a side effect profile that is generally favorable to our traditional therapies," said Dr. Edward Garon, senior author of the paper.

Indeed, PD-1 immunotherapy utilizes the antibody pembrolizumab, which is significantly less toxic to cancer patients than chemicals used in chemotherapy.

NSCLC like squamous cell carcinoma, adenocarcinoma, and large cell carcinoma are the most common types of lung cancer, making up 85 percent of all cases of lung cancer (American Cancer Society). Lung cancer is the leading cause of cancer death.

"This treatment provides real hope of long-lasting responses," Garon added.

For more about lung cancer, watch the following video.

Source: University of California, Los Angeles
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
MAR 19, 2020
Drug Discovery & Development
MAR 19, 2020
Could a 1949 Malaria Drug Treat COVID-19?
In the race to halt the current coronavirus pandemic, scientists, health experts and even Elon Musk are considering chlo ...
MAR 11, 2020
Neuroscience
MAR 11, 2020
Categories of Memory Work Together to Form Abstract Thought
Indiana University New research from the University of Trento shows how areas of the brain work to recall complex semant ...
APR 13, 2020
Immunology
APR 13, 2020
Macrophages: An Origin Story
Macrophages are well-known defense cells of the immune system, responsible for utilizing the cellular breakdown process ...
APR 22, 2020
Drug Discovery & Development
APR 22, 2020
Only 3% of COVID-19 Antibody Tests Approved by FDA
So far, only 3% of at least 90 COVID-19 antibody tests in the US have been approved by the Food and Drug Administration ...
MAY 15, 2020
Immunology
MAY 15, 2020
Support the Microbiome So the Immune System Can Do Its Job
Research has long connected the human microbiome and immune system function, and now a recent study pinpoints a key poin ...
MAY 26, 2020
Immunology
MAY 26, 2020
The Hunt for Rare Immune Cells, to InfinityFlow and Beyond
The immune landscape is staggeringly complex, with a myriad of genetically and functionally distinct immune cell subpopu ...
Loading Comments...